MADISON, Wis., March 4, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 36th Annual Roth Conference. The management team is scheduled to take part in a fireside chat on Monday, March 18, 2024 at 12:30pm PST / 3:30pm EST.
A live webcast of the fireside chat can be accessed on the Accuray website at investors.accuray.com. A replay will be available on the company's website following the event. The webcast replay of the presentation will begin about one hour after the conclusion of the live presentation and will be available for 90 days.
The 36th Annual Roth Conference will connect institutional investors with companies from diverse industry sectors. Companies will deliver on-demand presentations and participate in investor meetings.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.
Investor Contact
Aman Patel, CFA
Investor Relations, ICR-Westwicke
+1 (443) 450-4191
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.69 |
Daily Change: | -0.07 -3.98 |
Daily Volume: | 841,498 |
Market Cap: | US$190.500M |
October 08, 2025 September 30, 2025 September 26, 2025 September 11, 2025 August 13, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load